PDF(Pubmed)
Abstract：
Acne vulgaris is a multifaceted disease characterized by inflammatory and noninflammatory lesions. Topical combination therapies offer a multifaceted approach to acne treatment, with synergistic effects and a broad spectrum of action against multiple factors in acne pathogenesis in one single formulation. Clindamycin phosphate/benzoyl peroxide/adapalene, a combination therapy consisting of clindamycin phosphate 1.2%, benzoyl peroxide (BPO) 3.1%, and adapalene 0.15%, is a novel treatment, the only FDA-approved triple combination drug that offers effective treatment of acne vulgaris. This review aims to provide information on clindamycin phosphate/benzoyl peroxide/adapalene and review the literature on combination topical acne medications approved in the United States. This search was conducted on topical combination therapies for acne, their efficacy, adverse effects, and impacts on quality of life with a specific focus on the newly approved clindamycin phosphate/benzoyl peroxide/adapalene and its sub-component dyads, along with other combinations. PubMed, SCOPUS, Embase, Cochrane, and Web of Science databases were searched for publications in 2018-2023. Primary sources were given priority, and secondary sources such as other reviews were considered to supplement any missing information. It was found that various topical dyad and triad combinations exist for acne vulgaris, including adapalene/BPO, tazarotene/clindamycin, clindamycin/BPO, adapalene/clindamycin, topical tretinoin/azelaic acid, topical tretinoin/BPO, and clindamycin phosphate/benzoyl peroxide/adapalene. Dyad and triple combinations represent a promising, convenient solution for acne management, potentially improving patient adherence due to its single formulation. Clindamycin phosphate/benzoyl peroxide/adapalene exhibited significantly high efficacy in treating both inflammatory and noninflammatory lesions, a minimal side effect profile, although no significant changes in quality-of-life measures. Further research is indicated to assess its long-term efficacy and impact on other acne metrics such as cost, scarring, psychosocial implications, and impact on diverse patient populations.
摘要：
寻常痤疮是一种多面性疾病，以炎性和非炎性病变为特征。局部联合疗法为痤疮治疗提供了多方面的方法，在一个单一的制剂中具有协同作用和针对痤疮发病机理中的多种因素的广谱作用。克林霉素磷酸酯/过氧化苯甲酰/阿达帕林，由克林霉素磷酸酯1.2%组成的联合疗法，过氧化苯甲酰(BPO)3.1%,和阿达帕林0.15%，是一种新颖的治疗方法，唯一的FDA批准的三联组合药物，提供有效治疗寻常痤疮。这篇综述旨在提供有关克林霉素磷酸酯/过氧化苯甲酰/阿达帕林的信息，并回顾美国批准的联合局部痤疮药物的文献。这项搜索是针对痤疮的局部组合疗法进行的，其功效,不利影响，以及对生活质量的影响，特别关注新批准的克林霉素磷酸酯/过氧化苯甲酰/阿达帕林及其亚组分二重体，以及其他组合。PubMed,Scopus,Embase,科克伦,在2018-2023年搜索了WebofScience数据库的出版物。主要来源被优先考虑，和次要来源，如其他评论被认为是补充任何缺失的信息。发现寻常痤疮存在各种局部二元和三元组合，包括阿达帕林/BPO，他扎罗汀/克林霉素，克林霉素/BPO，阿达帕林/克林霉素，外用维甲酸/壬二酸，外用维甲酸/BPO，和克林霉素磷酸酯/过氧化苯甲酰/阿达帕林。Dyad和三重组合代表了一个有希望的，方便的痤疮管理解决方案，由于其单一配方，可能会改善患者的依从性。克林霉素磷酸酯/过氧化苯甲酰/阿达帕林在治疗炎性和非炎性病变方面均表现出显着的高疗效。最小的副作用，尽管生活质量指标没有显著变化。进一步的研究表明，以评估其长期疗效和对其他痤疮指标的影响，如成本，疤痕,心理社会影响，以及对不同患者人群的影响。
